Roche Completes Biopharma Acquisition Worth Up To $1.5B
The Swiss multinational Roche said its acquisition of U.S. genetic engineering company Poseida Therapeutics, intended to bolster Roche's development of new cancer treatments, will be completed Wednesday, with the transaction potentially...To view the full article, register now.
Already a subscriber? Click here to view full article